Detection of mCRPC in ADT Naïve
October 11, 2013
Podcast with Dr. Adam Kibel, summarizing the poster "Metastatic Disease Detection is an Important Cause of Screen Failures in a Phase II Trial Evaluating the Optimal Sequence of Androgen Deprivation Therapy and Sipuleucel-T in Hormone-Naïve Patients with Biochemically-Recurrent Prostate Cancer (BRPC)" presented at the European Cancer Congress (ECCO) in Amsterdam, September 29 to October 1, 2013
This poster presents a data analysis from the Phase II study that indicated a high frequency of radiographic metastatic disease in the setting of hormone-naïve BRPC, which highlights the importance of screening for metastases in this early-stage patient population.
Click HERE to read the abstract and poster